Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | Dave Fornell, Editor

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
News | Cardiac Imaging

November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women ...

Home November 17, 2020
Home
News | Pharmaceuticals

November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary ...

Home November 17, 2020
Home
News | Cath Lab

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

Home November 16, 2020
Home
News | Peripheral Artery Disease (PAD)

November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to ...

Home November 13, 2020
Home
News | Hemodynamic Support Devices

November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE ...

Home November 12, 2020
Home
Videos | Coronavirus (COVID-19)

Keith Ellis, M.D., is the director of cardiovascular services and the director of the Chest Pain Center at Houston ...

Home November 10, 2020
Home
An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases at RSNA 2019. Photo by Dave Fornell
Feature | Radiation Dose Management | Dave Fornell, Editor

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

Home November 04, 2020
Home
News | Drug-Eluting Balloons

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

Home November 03, 2020
Home
News | Robotic Systems

November 3, 2020 – Robocath, a company commercializing cardiovascular cath lab robotic systems, announced creation of ...

Home November 03, 2020
Home
The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020
Feature | AHA | Dave Fornell, Editor

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual ...

Home November 20, 2020
Home
Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect
Feature | FFR Technologies | Dave Fornell, Editor

Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous ...

Home October 30, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
News | Atrial Fibrillation

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one ...

Home October 26, 2020
Home
Subscribe Now